Trade Show

Meet Datwyler at
Chinese Biopharmaceutical Association - China

Elastomer Expertise for GLP-1 Injectables and Container Closure Innovation at China's Premier Biologics Event

Visit Datwyler at Booth #D60 at CBA-China 2026 in Wuxi, May 8–10, where David Qiu, Key Account Manager, presents on the technical challenges of elastomer components for GLP-1 injectable drug packaging — bringing Datwyler's deep container closure expertise to one of China's most important biologics and pharmaceutical industry forums.

Date May 8, 2026 – May 10, 2026

Location Wuxi International Conference Center | Wuxi, China

Details Booth #D60

Schedule a Meeting

Event Overview

Where GLP-1 Packaging Challenges Meet Elastomer Innovation

CBA-China brings together China's leading biologics manufacturers, CDMOs, pharmaceutical developers, and packaging specialists — and Datwyler will be there to engage with the teams at the forefront of the country's rapidly expanding GLP-1 and injectable drug market. David Qiu, Key Account Manager at Datwyler, takes the stage to present on the technical challenges of elastomer components for GLP-1 injectable drug packaging, addressing the specific material science, compatibility, and performance demands that this fast-growing therapeutic category places on primary packaging systems. At Booth #D60, attendees can connect with Datwyler's regional and global experts to explore our comprehensive portfolio of container closure systems, NeoFlex™ and OmniFlex® elastomer platforms, and drug delivery components — all engineered to meet the quality, regulatory, and scalability demands of China's domestic and export-focused pharmaceutical industry.

Attend David Qiu's presentation — "Technical Challenges in the Elastomer Components for Drug Packaging of GLP-1 Injectables" — for expert insight into the material science, compatibility, and functional performance requirements that define container closure system selection for GLP-1 drug packaging
Visit Booth #D60 to explore Datwyler's NeoFlex™ and OmniFlex® elastomer platforms, container closure systems, and drug delivery components engineered for China's growing GLP-1 and injectable pharmaceutical market
Connect with Datwyler's regional and global experts in Wuxi for 1-on-1 technical consultations on component selection, regulatory compliance, and packaging solutions for your GLP-1 or biologics program

Featured Presentations

Presentation Details

Technical Challenges in the Elastomer Components for Drug Packaging of GLP-1 Injectables

Date & Time May 10, 2026 • 10:05 AM

As GLP-1 therapies continue their rapid global expansion — driven by growing demand for injectable treatments in diabetes, obesity, and metabolic disease — the performance requirements placed on elastomeric container closure components have never been more precise or more consequential. In this presentation, David Qiu, Key Account Manager at Datwyler, examines the specific technical challenges that GLP-1 injectable drug packaging poses for elastomeric components — from material compatibility and extractables and leachables profiles to functional performance requirements including gliding force, break-loose force, and container closure integrity. Drawing on Datwyler's deep expertise in elastomer science and GLP-1 drug delivery, David provides pharmaceutical manufacturers and CDMOs with practical insight into how component selection, coating technology, and manufacturing quality standards directly impact drug product stability, regulatory compliance, and patient safety across the full GLP-1 injectable packaging lifecycle.

View David Qiu

Speaker Spotlight

Meet the Speakers

David Qiu

Key Account Manager | Datwyler

David Qiu graduated from China Pharmaceutical University with a degree in Pharmaceutical Formulation and Pharmaceutical Engineering. Prior to joining Datwyler, he held positions in the R&D departments of companies such as Fresenius. He has nearly 20 years of experience in the R&D of pharmaceuticals and medical devices, with extensive expertise in the analytical testing of packaging materials, formulations, and raw materials, as well as in the study of elemental impurities and extractables and leachables.

Solutions Spotlight

What We're Showcasing at Chinese Biopharmaceutical Association - China

Explore the solutions and technologies most relevant to this event.

Featured Solution

Presentation: Technical Challenges in Elastomer Components for GLP-1 Injectable Drug Packaging

David Qiu, Key Account Manager at Datwyler, examines the specific material science, compatibility, and functional performance challenges that GLP-1 injectable drug packaging places on elastomeric container closure components — providing pharmaceutical manufacturers and CDMOs with expert guidance on component selection, extractables and leachables considerations, and the quality standards required to support GLP-1 drug product development and commercialization.

Featured Solution

NeoFlex™ & OmniFlex® Platforms for GLP-1 and Biologic Drug Delivery

Datwyler's NeoFlex™ and OmniFlex® elastomer platforms are engineered to meet the demanding purity, compatibility, and functional performance requirements of GLP-1 and biologic drug products — featuring ultra-low extractable formulations, proprietary fluoropolymer coating technology, optimized gliding performance, and ultra-clean FirstLine® manufacturing standards designed to support sensitive injectable drug formulations.

Featured Solution

Pharmaceutical Packaging Solutions for China's Growing Market

Datwyler presents its comprehensive portfolio of container closure systems, elastomers, and drug delivery components tailored for China's pharmaceutical market — addressing the quality, regulatory, and scalability demands of a rapidly expanding domestic and export-focused industry, with regional and global expertise available to support drug manufacturers at every stage of development and commercialization.

Additional Information